NASDAQ: CRIS
Curis Inc Stock

$3.22-0.12 (-3.59%)
Updated Feb 7, 2025
CRIS Price
$3.22
Fair Value Price
-$2.80
Market Cap
$27.26M
52 Week Low
$2.86
52 Week High
$17.49
P/E
-0.41x
P/B
-3.12x
P/S
3.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.26M
Earnings
-$45.48M
Gross Margin
98.7%
Operating Margin
-443.35%
Profit Margin
-443.3%
Debt to Equity
-5.86
Operating Cash Flow
-$40M
Beta
0.64
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CRIS Overview

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CRIS's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

D
Value
B
Growth
F
Momentum
C
Sentiment
C
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
CRIS
Ranked
#136 of 556

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important CRIS news, forecast changes, insider trades & much more!

CRIS News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRIS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CRIS ($3.22) is overvalued by 215.2% relative to our estimate of its Fair Value price of -$2.80 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRIS ($3.22) is not significantly undervalued (215.2%) relative to our estimate of its Fair Value price of -$2.80 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRIS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRIS due diligence checks available for Premium users.

Valuation

CRIS fair value

Fair Value of CRIS stock based on Discounted Cash Flow (DCF)

Price
$3.22
Fair Value
-$2.80
Undervalued by
215.20%
CRIS ($3.22) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRIS ($3.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRIS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CRIS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.41x
Industry
-146.27x
Market
30.7x

CRIS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-3.12x
Industry
4.94x

CRIS's financial health

Profit margin

Revenue
$2.9M
Net Income
-$10.1M
Profit Margin
-344.3%
CRIS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CRIS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$42.5M
Liabilities
$51.2M
Debt to equity
-5.86
CRIS's short-term assets ($26.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRIS's long-term liabilities ($29.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRIS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRIS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.9M
Investing
$18.3M
Financing
-$1.5M
CRIS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CRIS vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CRISC$27.26M-3.45%-0.41x-3.12x
RNXTC$27.84M-20.55%-2.04x3.94x
PULMC$26.44M-4.49%-2.74x2.42x
CVM$28.09M-3.56%-0.74x2.18x
CGTXD$26.38M-0.78%-0.65x1.82x

Curis Stock FAQ

What is Curis's quote symbol?

(NASDAQ: CRIS) Curis trades on the NASDAQ under the ticker symbol CRIS. Curis stock quotes can also be displayed as NASDAQ: CRIS.

If you're new to stock investing, here's how to buy Curis stock.

What is the 52 week high and low for Curis (NASDAQ: CRIS)?

(NASDAQ: CRIS) Curis's 52-week high was $17.49, and its 52-week low was $2.86. It is currently -81.59% from its 52-week high and 12.59% from its 52-week low.

How much is Curis stock worth today?

(NASDAQ: CRIS) Curis currently has 8,466,957 outstanding shares. With Curis stock trading at $3.22 per share, the total value of Curis stock (market capitalization) is $27.26M.

Curis stock was originally listed at a price of $2,438.00 in Aug 1, 2000. If you had invested in Curis stock at $2,438.00, your return over the last 24 years would have been -99.87%, for an annualized return of -24.14% (not including any dividends or dividend reinvestments).

How much is Curis's stock price per share?

(NASDAQ: CRIS) Curis stock price per share is $3.22 today (as of Feb 7, 2025).

What is Curis's Market Cap?

(NASDAQ: CRIS) Curis's market cap is $27.26M, as of Feb 9, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Curis's market cap is calculated by multiplying CRIS's current stock price of $3.22 by CRIS's total outstanding shares of 8,466,957.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.